Corvus Pharmaceuticals, Inc. (CRVS) Free cash flow 2016–2025
Corvus Pharmaceuticals, Inc. (CRVS) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$33.0MFY2025 · since FY2016: -$30.1M → -$33.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$33.0M | — |
| FY2023 | -$24.0M | +12.2% |
| FY2022 | -$27.3M | +25.7% |
| FY2021 | -$36.7M | -5.4% |
| FY2020 | -$34.9M | +6.7% |
| FY2019 | -$37.3M | +9.7% |
| FY2018 | -$41.3M | +11.0% |
| FY2017 | -$46.5M | -54.6% |
| FY2016 | -$30.1M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More CRVS financial trends
CRVS RevenueCRVS Net incomeCRVS Net marginCRVS Gross profitCRVS Gross marginCRVS Operating incomeCRVS Operating marginCRVS Operating cash flowCRVS Capital expendituresCRVS Return on equityCRVS Stock buybacksCRVS Dividends paidCRVS Total assetsCRVS Total liabilitiesCRVS Shareholders’ equityCRVS overview →